C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy

Blood Adv. 2022 Dec 13;6(23):6071-6074. doi: 10.1182/bloodadvances.2022008395.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / drug therapy
  • Thrombotic Microangiopathies* / chemically induced

Substances

  • Antineoplastic Agents